■人们越来越认识到营养保健品在治疗镰状细胞疾病方面的益处,但很少有关于其使用的报道。营养食品是提供医疗或健康益处的食品或食品部分。它们包括植物药,功能性食品和药用食品。这是关于在尼日利亚一小批镰状细胞疾病儿童的管理中使用营养品的初步报告。
■临床结果的回顾性审计是在位于联邦首都地区的大脑中心进行的,阿布贾,尼日利亚。孩子们,1至12岁,在基线时和开始服用保健品鸡尾酒后6个月时,使用客观分级工具评估镰状细胞贫血.体重变化,确定了血细胞比容和镰状细胞危象的频率。由于样本量小,Wilcoxon符号检验用于确定体重平均值之间的相似性/差异,PCV,以及在7个月和6个月时获得的危机。
■对10名镰状细胞性贫血患儿进行营养品治疗。儿童的平均年龄为8.5(范围1-12)岁。Aroga免疫支持是给孩子的营养鸡尾酒中最常见的组成部分。平均体重有所上升(从21.8公斤上升到23.0公斤,p值0.236)和与基线时获得的值相比,六个月时的平均血细胞比容(22.8至27.2,p值0.011)。与基线时获得的值相比,六个月时镰状细胞危机的平均频率也有所下降(从7.4降至3.2,p值0.011)。总的来说,十名儿童中有八名表现出中度至良好的临床改善。没有任何证据表明任何儿童对药物有任何不良反应。
■结果表明,在儿童镰状细胞性贫血的治疗中,使用营养品可能是有益的。然而,结果是初步的,需要更有力的证据。需要使用较大样本量的对照临床试验。这种非常规疗法的临床试验应该非常小心地进行,并关注参与者的安全。
UNASSIGNED: There is growing recognition of the benefits of nutraceuticals in the management of sickle cell disease but a scarcity of
reports on their use. Nutraceuticals are food or parts of food that provide medical or health benefits. They include botanicals, functional foods and medicinal foods. This is a preliminary report on the use of nutraceuticals in the management of a small cohort of children with sickle cell disease in Nigeria.
UNASSIGNED: The retrospective audit of clinical outcomes was carried out at a brain center located within the Federal Capital Territory, Abuja, Nigeria. Children, aged 1 to 12 years, presenting with sickle cell anaemia were evaluated at baseline and at six months after the commencement of a cocktail of nutraceuticals using an objective grading tool. Changes in weight, haematocrit and frequency of sickle cell crises were determined. On account of the small sample size, Wilcoxon sign test was used to determine the similarity / difference between the average values of weight, PCV, and crises obtained at enro7lment and six months.
UNASSIGNED: Ten children with sickle cell anaemia were placed on nutraceuticals therapy. The average age of the children was 8.5 (range 1 - 12) years. Aroga immune support was the commonest component of the nutraceutical cocktail given to the children. There was a rise in average weight (from 21.8 to 23.0 Kg, p-value 0.236) and average haematocrit (22.8 to 27.2, p-value 0.011) at six months compared to values obtained at baseline. There was also a fall in the average frequency of sickle cell crises at six months compared to values obtained at baseline (from 7.4 to 3.2, p-value 0.011). Overall, eight out of the ten children showed moderate to good clinical improvement. There was no documentation of any adverse reaction to the medications in any of the children.
UNASSIGNED: The results suggest that the use of nutraceuticals may be beneficial in the management of sickle cell anaemia in children. However, the results are preliminary and will require stronger evidence. There is a need for controlled clinical trials for using larger sample sizes. Such clinical trials of unconventional therapies should be conducted with great care and concern for the safety of the participants.